Improving treatment for triple-negative breast cancer using anti-NMDAR antibodies
Optimizing Anti-NMDAR Antibodies for Triple-Negative Breast Cancer Therapy
This study is looking at a new treatment for triple-negative breast cancer that uses special antibodies to target a specific receptor in cancer cells, and it aims to make sure the treatment is effective while keeping any side effects in check, so it can help patients with this tough type of breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project ID | NIH-11108587 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy for triple-negative breast cancer (TNBC) by utilizing antibodies that target the N-methyl-D-aspartate receptor (NMDAR), which is often overexpressed in TNBC cells. The study aims to differentiate the anti-tumor effects of these antibodies from their potential neurological side effects, which can include severe complications like psychosis and seizures. Researchers will use advanced imaging techniques to understand how these antibodies interact with NMDAR and will test their effectiveness in specially designed mouse models of TNBC. The goal is to create a safe and effective treatment option for patients with this aggressive form of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from new therapeutic options.
Not a fit: Patients with other types of breast cancer or those who do not express NMDAR may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel and effective therapy for patients with triple-negative breast cancer, potentially improving survival rates.
How similar studies have performed: While the use of antibodies in cancer therapy is well-established, this specific approach targeting NMDAR in triple-negative breast cancer is novel and has not been extensively tested.
Where this research is happening
Cold Spring Harbor, United States
- Cold Spring Harbor Laboratory — Cold Spring Harbor, United States (Active)
Researchers
- Principal investigator: Janowitz, Tobias — Cold Spring Harbor Laboratory
- Study coordinator: Janowitz, Tobias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.